Welcome to our dedicated page for Core Scientific, Inc./tx SEC filings (Ticker: CORZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific, Inc./tx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific, Inc./tx's regulatory disclosures and financial reporting.
Core Scientific, Inc. (CORZ) Chief Legal and Administrative Officer Todd M. Duchene reported selling a total of 10,000 shares of common stock on July 27, 2026, in three transactions reported as open-market or private sales.
The sales comprised 8,300 shares at $20.7469, 1,600 shares at $21.8925, and 100 shares at $22.4900 per share. The 8,300‑ and 1,600‑share trades were executed at weighted average prices within ranges of $20.47–$21.42 and $21.47–$22.44, respectively. All transactions were effected under a Rule 10b5-1 trading plan adopted on December 5, 2025.
Core Scientific, Inc. appointed Mark W. Adams to its Board of Directors, effective July 29, 2026, increasing the board to seven directors. The board determined he qualifies as an independent director under Sarbanes-Oxley and Nasdaq listing standards and he will receive cash and equity compensation consistent with other non-employee directors.
Adams, age 62, brings extensive technology leadership experience, including roles as President and CEO of Penguin Solutions from 2020 to 2026, CEO of Lumileds from 2017 to 2019, and President of Micron Technology from 2012 to 2016. He also serves on the boards of Seagate Technology and Cadence Design Systems. There are no family relationships or related-party transactions disclosed in connection with his appointment.
Core Scientific designs, builds and operates large-scale, purpose-built data centers for high-density colocation services supporting AI-related workloads and is repurposing remaining digital asset mining facilities to support this colocation business.
Core Scientific, Inc. reported Q2 2026 results showing a continued shift toward high‑density colocation while still posting GAAP net losses. Total revenue was $164.2 million, led by colocation revenue of $136.7 million as more AI/HPC capacity came online and bitcoin self‑mining activity decreased.
Despite a consolidated gross margin of 43% and Q2 adjusted EBITDA of $41.1 million, net loss was $1.16 billion, mainly from a $1.05 billion increase in the fair value of warrant liabilities and previously recorded $266.5 million impairments of mining‑related assets. Long‑term debt increased after a $3.30 billion issuance of 7.75% Senior Secured Notes due 2031.
Liquidity included cash, cash equivalents and restricted cash of $2.55 billion and bitcoin holdings valued at $49.7 million as of June 30, 2026. The company controlled about 2.1 GW of gross utility power capacity and disclosed $6.09 billion of contracted future operating lease payments from colocation customers, plus additional long‑term leases with AMD and Neocloud signed after quarter‑end.
Core Scientific, Inc. reported Q2 2026 total revenue of $164.2 million, up from $115.2 million in Q1 2026, driven by colocation revenue of $136.7 million. Gross profit was $70.0 million with a 43% gross margin, and Adjusted EBITDA reached $41.1 million.
The company recorded a net loss of $1.16 billion, mainly from a $1.05 billion non-cash increase in the fair value of warrants and contingent value rights. Liquidity totaled $1.82 billion, while total liabilities of $7.68 billion exceeded assets of $5.26 billion, resulting in a stockholders’ deficit.
Recent high-density colocation milestones include expanding leased customer power capacity to approximately 1.1 GW, representing more than $24 billion of potential contracted revenue, and an AMD partnership that could support up to 2.5 GW of leasable capacity with about 530 MW anchored under 15-year agreements.
Core Scientific entered into long-term AI infrastructure arrangements with AMD and Neocloud and issued AMD a warrant linked to those leases. On July 27, 2026 the company granted AMD a warrant for up to 30 million shares at $23.47 per share, vesting at 12,222 shares per megawatt of critical IT load; about 6.5 million shares vested immediately. The warrant is exercisable subject to vesting, expires July 27, 2031, and was issued in reliance on the Section 4(a)(2) private-offering exemption.
New lease agreements cover 377 MW of critical IT capacity for AMD and 152 MW for Neocloud across multiple U.S. sites, each for 15-year terms with three five-year options. AMD also receives a reservation right for up to 1,925 MW of additional capacity through December 28, 2028, plus credit-support arrangements around Neocloud’s leases. A related partnership release highlights more than 500 MW of U.S. capacity beginning in 2027 with expansion potential to 2.5 GW.
An investor presentation cites roughly $24B+ of contracted capacity and about $1.8B in average annualized colocation GAAP revenue, supported by a CoreWeave contract covering ~590 MW with $10B+ in revenue potential. Colocation revenue was $136.7M in the second quarter of 2026, and pro forma fully diluted shares are about 508 million.
Core Scientific, Inc. reported that CEO Adam Taylor Sullivan had 15,584 shares of common stock withheld on 2026-07-16 to satisfy tax obligations upon the vesting of restricted stock units at $22.72 per share, leaving 4,436,426 shares held directly.
Core Scientific, Inc. reported that Chief Legal and Administrative Officer Todd M. Duchene had 4,325 shares of Common Stock withheld on July 16, 2026 to satisfy withholding tax obligations upon the vesting of restricted stock units, at $22.72 per share. After this tax-withholding disposition, he directly holds 2,009,101 Common Stock shares.
Todd M. Duchene, an officer of Core Scientific, Inc., reported two open-market sales totaling 10,000 shares of Common Stock on July 13, 2026, at weighted average prices of $22.4301 and $23.0100 per share.
The transactions were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 5, 2025.
Core Scientific, Inc. officer Todd M. Duchene reported an open-market sale of 10,000 shares of Common Stock on July 6, 2026 at a weighted average price of $22.6254 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre-scheduled rather than discretionary. Following this sale, Duchene directly holds 2,023,426 shares of Core Scientific common stock.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 disclosing scheduled resale activity by the Todd Duchene Revocable Trust under a Rule 10b5-1 plan, showing repeated sales of 10,000 shares on multiple dates in April–June 2026.
The filing also lists Restricted Stock Units: 21,673 (02/22/2024) and a Tender: 118,327 (12/13/2024) as securities referenced in the notice.